Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3), a medical device company developing the IzoView dedicated breast CT imaging system, has closed a non-brokered private placement financing for gross proceeds of $150,000. The Vancouver-based company issued 750,000 units at $0.20 per unit, with proceeds directed toward general working capital. The closing follows the company's September 25 announcement outlining the planned Offering, and investors in the breast cancer imaging space may be watching how the company deploys these funds.

Key Points

  • Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) is a medical device company commercialising the IzoView breast CT imaging system
  • The company closed a non-brokered private placement, issuing 750,000 units at $0.20 per unit for gross proceeds of $150,000
  • Each unit includes one common share and one warrant exercisable at $0.30 per share for three years from closing
  • All issued securities are subject to a four-month-and-one-day statutory hold period; the company noted IzoView has not yet received regulatory approval or clearance for sale

Structure of the IZO Private Placement Units and Warrant Terms

Each of the 750,000 units issued under the Offering comprises one common share and one transferable warrant. The release states that each warrant entitles the holder to acquire one additional common share at an exercise price of $0.30 for a period of three years from the closing date. The blended structure provides initial funding while offering warrant holders potential upside participation if Izotropic's share price rises above the $0.30 exercise threshold during the three-year window. The company noted that completion of the Offering remains subject to receipt of all necessary regulatory approvals.

Use of Proceeds and Working Capital Position

Izotropic disclosed that the $150,000 in gross proceeds will be allocated entirely to general working capital. The company did not disclose a detailed breakdown of anticipated expenditures or how long the proceeds are expected to sustain operations. For a medical device company at the commercialisation stage, working capital financing is a common requirement, and investors may be watching whether additional capital raises accompany development milestones for the IzoView system. The company has not provided guidance on its current cash runway or broader financing strategy in this announcement.

IzoView Breast CT System and Commercialisation Status

Izotropic describes itself as a medical device company focused on commercialising IzoView, a dedicated breast CT imaging system intended for more accurate screening and diagnosis of breast cancers. The company's release explicitly cautions that IzoView has not yet been approved or cleared for sale by any regulatory authority. This disclosure underscores that Izotropic remains in a pre-revenue, pre-approval phase, and investors should factor regulatory risk into any assessment of the company's development timeline and commercial prospects.